COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    Apremilast as Treatment for Chronic Itch
Previous Study | Return to List | Next Study

A Study Examining the Medication Apremilast as Treatment for Chronic Itch

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03239106
Recruitment Status : Completed
First Posted : August 3, 2017
Results First Posted : April 20, 2020
Last Update Posted : October 30, 2020
Celgene Corporation
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.

Condition or disease Intervention/treatment Phase
Itch Drug: Apremilast Phase 2

Detailed Description:
There is no FDA-approved medication for chronic idiopathic pruritus (CIP). Apremilast has demonstrated notable activity and is approved for treatment in other pruritic inflammatory skin conditions such as psoriasis. The drug is currently being investigated as therapy for atopic dermatitis. Additionally, the investigators have preliminary data to suggest that apremilast's anti-inflammatory properties may work via neuromodulation targeting neuronal cytokine pathways. The proposed study plans to assess the efficacy of apremilast 30 mg BID in the setting of CIP. Durable response to a medication is typically seen within one to two months of starting an efficacious medication in subjects who respond. Therefore, the investigators have designed this study to end at Week 16 to definitively determine efficacy and conclude the study with confidence with regard to both efficacy and failure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open label
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Study of Apremilast in Chronic Idiopathic Pruritus
Actual Study Start Date : December 1, 2017
Actual Primary Completion Date : October 31, 2018
Actual Study Completion Date : September 19, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Itching
Drug Information available for: Apremilast

Arm Intervention/treatment
Experimental: open label
All participants will receive Apremilast 30 mg BID.
Drug: Apremilast
Apremilast 30 mg BID daily
Other Name: Otezla

Primary Outcome Measures :
  1. Absolute NRS Itch Score at Week 16 (End of Treatment) [ Time Frame: Week 16 ]

    Participants will complete a Numeric Rating Scale for itch (0 representing "no itching" through 10 representing "worst itch imaginable") will be recalled from prior 24 hours and the prior week.

    0 is the best score (minimum) and 10 is the worst score (maximum) in terms of clinical outcome. This is an ordinal scale that runs from 0 to 10.

Secondary Outcome Measures :
  1. Absolute DLQI at Week 16 [ Time Frame: Week 16 ]

    Participants will complete a 10 question Dermatology Quality of Life survey at baseline through Week 16

    The DLQI is a numerical scale that scores multiple parameters of skin symptoms on a scale from 0 to 30. 0-1 = no effect at all on a patient's life (most favorable clinical outcome and minimum score), 1-5 = small effect on patient's life, 6-10 = moderate effect on patient's life, 11-20 = very large effect on patient's life, 21-30 = extremely large effect on patient's life (worse clinical outcome and maximum score).

  2. NRS at Screening, Baseline and Weeks 2,4,8,12,16,and 18 [ Time Frame: Screening through Week 18 (follow up visit) ]
    Participants' itch will be measured utilizing the Numeric Rating Scale for itch

  3. DLQI at Screening, Baseline, and Weeks 2,4,8,12,16 and 18 [ Time Frame: Screening through Week 18 (follow up visit) ]
    Participants will complete a 10 question Dermatology Life Quality Index questionnaire at Screening, Baseline, and Weeks 2,4,8,12,16,18.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Key Inclusion Criteria: A subject who meets all of the following criteria may be included in the study:

  • Male and non-pregnant, non-lactating female subjects aged 18 years or older
  • Diagnosed with chronic idiopathic pruritus (CIP) with an NRS Itch Score of ≥ 7 at both Screening and Baseline
  • Diagnosis of CIP for at least 6 weeks prior to screening
  • Willingness to avoid pregnancy or fathering of children
  • Ability and willingness to provide written informed consent
  • Willing and able to comply with all study requirements and restrictions
  • Willing to not participate in any other interventional trial for the duration of their participation
  • Subjects must be in good health as determined by medical history, physical examination, electrocardiogram, clinical laboratory tests and vital signs
  • Failure of a course 2-week course of treatment with topical triamcinolone 0.1% ointment BID
  • Histopathological demonstration of skin eosinophils, mast cell activation, lymphocytic infiltration, and/or dermal edema

Exclusion Criteria:

Key Exclusion Criteria: A subject who meets any of the following criteria will be excluded from the study:

  • Chronic pruritus due to a defined primary dermatologic disorder (e.g., atopic dermatitis, psoriasis, etc.)
  • Patients with a prior diagnosis of excoriation disorder
  • Use of topical treatments for CIP (other than bland emollients) within 1 week of Baseline
  • Systemic immunosuppressive or immunomodulating drugs within 4 weeks of Baseline
  • Subjects with cytopenias at screening, defined as:

    • Leukocytes < 3 × 109/L.
    • Neutrophils < lower limit of normal.
    • Lymphocytes < 0.5 × 109/L
    • Hemoglobin < 10 g/dL.
    • Platelets < 100 × 109/L.
  • Unwilling or unable to follow medication restrictions described in Section 5.6.3, or unwilling or unable to sufficiently washout from use of restricted medication
  • Under medical treatment for a skin disease with a therapy listed in the prohibited medications section that may influence the results of the study
  • Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal gastrointestinal, endocrine or metabolic dysfunction unless currently controlled and stable, including (but not limited to) the following: Positive for Hepatitis C antibody test (anti-HCF) Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) Positive for HIV (DUO test, p24 antigen)
  • Active malignancy
  • Active substance abuse or history of substance abuse within 6 months of screening
  • History (including family history) or current evidence of congenital long QT syndrome or known acquired QT prolongation
  • Exposure to any investigational medication, including placebo, within 60 days of the Baseline Visit
  • Subjects who had previously received apremilast
  • Subjects with severely impaired liver function (Child-Pugh Class C) or end-stage renal disease on dialysis or at least 1 of the following:

    • Serum creatinine > 1.5 mg/dL
    • Alanine aminotransferase or aspartate aminotransferase ≥ 1.5 × upper limit of normal
  • Anyone affiliated with the site or sponsor and/or anyone who may consent under duress
  • Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03239106

Layout table for location information
United States, Missouri
Washington University Division of Dermatology
Saint Louis, Missouri, United States, 63108
Sponsors and Collaborators
Washington University School of Medicine
Celgene Corporation
Layout table for investigator information
Principal Investigator: Brian S. Kim, MD Washington University School of Medicine
  Study Documents (Full-Text)

Documents provided by Washington University School of Medicine:
Informed Consent Form  [PDF] August 20, 2019

Layout table for additonal information
Responsible Party: Washington University School of Medicine Identifier: NCT03239106    
Other Study ID Numbers: CIP-ApremilastCC-10004
First Posted: August 3, 2017    Key Record Dates
Results First Posted: April 20, 2020
Last Update Posted: October 30, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Washington University School of Medicine:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Skin Manifestations
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents